The care of patients with difficult-to-control asthma ("difficult asthma") is challenging and costly. Despite high-intensity asthma treatment, these patients experience poor asthma control and face the greatest risk of asthma morbidity and mortality.
| INTRODUCTION
Patients whose asthma remains difficult-to-control despite highintensity treatment have the greatest risk of asthma morbidity and mortality.
1,2 Although patients with difficult-to-control asthma may have biologically severe disease, other factors are often at play. Severe asthma guidelines emphasize confirming the diagnosis of asthma, and addressing contributory factors and comorbidities, before phenotyping the pattern of inflammation. 3 Such an approach tacitly concedes the need to consider a range of issues before embarking on phenotype-driven biological treatment.
A number of extra-pulmonary comorbidities contribute to poor control in patients with difficult-to-control asthma, hereafter termed difficult asthma. 4 In such patients, these comorbidities may impact all three elements of difficult asthma assessment. Comorbidities may masquerade as asthma when a patient does not have asthma at all.
They may add to the burden of symptoms, impaired quality of life or exacerbation frequency. They may even constitute a distinct phenotype of severe asthma, as with obesity. 5 There is a progressive move towards identifying and treating individual "treatable traits." Comorbidities have been depicted as a distinct bundle of "treatable traits" in airway disease, 6 reinforcing the view that comorbidities play a significant role in chronic airway disease.
While guidelines recommend that comorbidities in difficult asthma should be addressed, a number of key questions remain.
This review will address each question directly and outline a pragmatic clinical approach to this challenging area. As many studies employ the term "severe asthma" to describe asthma patients on high-intensity treatment, we have included such patients under the umbrella of "difficult asthma." Comorbidities involving the lung (eg, bronchiectasis) or resulting from asthma treatments (eg, osteoporosis) fall outside the scope of this discussion.
| HOW COMMON ARE COMORBIDITIES
IN DIFFICULT ASTHMA?
| Allergic and nonallergic rhinitis
Rhinitis is common in asthma, and the prevalence is similar regardless of asthma severity. In the Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED) cohort, allergic rhinitis was present in 55% of severe asthma patients and 60% of nonsevere asthma patients, while nonallergic rhinitis was present in 15% of severe asthma patients and 11% of nonsevere asthma patients. 
| Chronic rhinosinusitis
Among asthma patients, the prevalence of chronic rhinosinusitis (CRS)
ranges from 22% to 42% 8, 9 and is higher in severe asthma, affecting 45% of patients in the Severe Asthma Research Program (SARP). 5 Similarly, the prevalence of nasal polyposis increases with asthma severity.
In mild, moderate and severe asthma patients, the prevalence of nasal polyposis was 4.8%, 9.6% and 44.6% respectively. 10 Based on a meta-analysis, the pooled prevalence of aspirin-exacerbated respiratory disease (AERD) is 7.2% in all asthmatics but 14.9% among severe asthmatics. 
| Gastroesophageal reflux
Gastroesophageal reflux disease (GERD) symptoms are present in 40%-80% of asthmatics, 12, 13 while objective evidence of gastroesophageal reflux (GER) on pH probe testing is found in 62%-72% of asthmatics. 14, 15 Gastroesophageal reflux disease (GERD) is most frequent among severe asthma patients. In the SARP cohort, GERD symptoms were present in only 12%-16% nonsevere asthma patients but 41% of severe asthma patients. 16 Findings in U-BIOPRED showed similar results. 
| Obstructive sleep apnoea
Studies using polysomnography to ascertain the prevalence of obstructive sleep apnoea (OSA) in the asthma population have not been reported although studies using symptoms are available. Snoring was present in 17.9% of patients with asthma, 17 while 39.5% of patients seen at a general asthma clinic were thought to be at high risk of OSA based on the Berlin questionnaire. 18 Among patients with difficult asthma, OSA was considered likely in 38.9% of patients based on a positive Berlin questionnaire or previous polysomnography (PSG). 19 Among unselected patients with severe asthma who underwent polysomnography, OSA was present in >80%.
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| Vocal cord dysfunction
The diagnosis of Vocal cord dysfunction (VCD) is challenging despite various investigation modalities. Direct visualization of abnormal vocal fold movement at laryngoscopy is the gold standard, but false negatives occur during asymptomatic periods. 22 Exercise, odour, histamine, methacholine and mannitol challenges have been used to increase the sensitivity of laryngoscopy. [22] [23] [24] [25] [26] [27] Spirometry, 28 dynamic
CT scanning 29 and questionnaires 30, 31 have also been used to diagnose VCD, with varying levels of diagnostic accuracy.
The prevalence of VCD is 19% 32 in asthma patients and 32% in difficult asthma patients. 19 One study directly comparing mild and severe asthma patients on dynamic CT confirmed a higher VCD prevalence among those with more severe asthma. 
| Obesity
Obesity is epidemic in Western populations, with a prevalence of 36% among US adults. 33 The prevalence of obesity in asthma in one
European study was 18% among nonsevere asthma patients, but 39% among severe asthma patients. 7 A specific obese phenotype of severe asthma has been identified in UK and US cohorts, 5, 34 but not in Asian cohorts where obesity rates are much lower. 
| Dysfunctional breathing
Dysfunctional breathing (DB) is a poorly defined syndrome with chemical (hypocapnia), mechanical (respiratory motion) and perceptual (patient symptom) components. 36 Based on the Nijmegen Questionnaire 37 and using a score ≥23, the prevalence of DB in asthma was 29% in a primary care setting and 24.4% in a secondary care setting. 38, 39 Using the same definition, the prevalence of DB in difficult asthma was higher, at 30%-64%. The highest prevalence of extra-pulmonary comorbidities is observed in difficult asthmatics compared to the general asthma population.
( Table 1 ). Not only are individual comorbidities common in difficult asthma, it is also common to find multiple comorbidities in each patient. 45 Published cohorts vary widely when reporting the prevalence of rhinitis, CRS, DB and VCD, even when drawn from the same general population. Such differences in the reported prevalence of comorbidities in difficult asthma are partly due to inconsistent definitions and diagnostic criteria, as detailed above. However, another important factor may be under-diagnosis. Even among asthma specialists, a proportion of comorbidities was overlooked when these were not assessed systematically. 46 The asthma. 64 Secondly, inflammatory subgroups in CRS mirror type 2 high and type 2 low inflammatory phenotypes observed in asthma. 34, 65 Thirdly, the pattern of inflammation within the upper and lower airways of individual patients is strongly concordant.
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The presence or absence of nasal polyps can also give an indication of the type of airway inflammation.
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| Influence on asthma outcomes
Among asthma patients, the presence of CRS predicts more asthma symptoms, 8 more frequent exacerbations 69, 70 and poorer quality of life. 8 In patients with difficult asthma, the presence of CRS increases the risk of frequent exacerbations by fourfold, even when adjusted for eosinophilic status. 19, 71 Sinusitis was independently associated with frequent exacerbations in the Severe Asthma Research Program (SARP) cohort 72 and the presence of CRS was incorporated into an asthma exacerbation risk prediction model. 
| Association with other comorbidities
Chronic rhinosinusitis (CRS) frequently coexists with obesity and depression in asthma. 74 Chronic rhinosinusitis may also trigger VCD through the direct physical stimulus of postnasal drip. The relationship between GERD and asthma is bidirectional. Oesophageal irritation may cause bronchoconstriction. In patients with known asthma and endoscopy-diagnosed reflux, acid infusion into the oesophagus worsened peak flow rate (PEFR) and airway resistance. 76 The observed bronchoconstriction is likely vagally mediated. 77 Acid infusion experiments also increased bronchial hyperresponsiveness in asthmatics. 78, 79 On the other hand, asthma may predispose to GERD. Methacholine-induced bronchoconstriction increases the frequency of GER and transient lower oesophageal sphincter relaxation. 80 Oral corticosteroid (OCS) administration also increases oesophageal acid contact time and reflux risk. 
| Influence on asthma outcomes
Among patients with asthma, the presence of GERD symptoms is associated with worse asthma symptoms and poorer quality of life 9,12 although GER per se does not affect lung function. 82 In patients with difficult asthma, the presence of GERD symptoms is an independent risk factor for frequent exacerbations. 71, 72 Gastroesophageal reflux disease was also associated with worse asthma symptoms and poorer quality of life. 
| Association with other comorbidities
Nocturnal GERD is associated with the development of rhinitis. 83 Gastroesophageal reflux and its associated condition, laryngopharyngeal reflux, are common triggers for vocal cord dysfunction, 84 probably by direct laryngeal irritation or neural reflex. 85, 86 Asthma patients more often have anxiety and depression if also diagnosed with GERD. Obstructive sleep apnoea (OSA) may worsen asthma by driving airway inflammation. 87 OSA alters oxidative balance in the airways through repeated hypoxia and reoxygenation. 88 Exhaled breath condensate of inflammatory and oxidative stress markers, IL-6 and 8-isoprostane, respectively, are increased in patients with OSA compared to obese controls and healthy controls. 88 These biomarkers can be suppressed by CPAP treatment. 89 Patients with OSA also have increased systemic inflammatory cytokines, endothelial T lymphocyte adherence, 90 increased sputum neutrophils 91 and heightened bronchial hyperresponsiveness. 
| Influence on asthma outcomes
Asthma patients with untreated OSA are more likely to have increased daytime and night-time asthma symptoms, even when controlled for other factors such as obesity, GERD and nasal disease. 93, 94 Patients also report a poorer asthma-related quality of life. Importantly, vocal cord adduction has also been observed to occur in bronchoconstriction. 102, 103 This may therefore represent an adaptation akin to pursed lip breathing, which increases intrinsic positive end-expiratory pressure and improves alveolar gas exchange. In patients with difficult asthma, it may be difficult to differentiate VCD occurring as a physiological response to airflow obstruction from a separate and symptomatic pathological entity.
Patients with VCD may be misdiagnosed as having asthma, while patients with both VCD and concomitant asthma may have misattribution of symptoms to asthma. [104] [105] [106] [107] Patients with VCD misdiagnosed as asthma have higher medication use and healthcare utilization. 108 High doses of inhaled corticosteroid and bronchodilator therapy can also result in laryngeal mucosal irritation, perpetuating further laryngeal dysfunction. 109 In difficult asthma, the presence of VCD is associated with a poorer quality of life. 
Obesity is also a risk factor for asthma misdiagnosis, 124 so objective tests to confirm variable airflow obstruction are particularly important. Obesity is associated with poorer asthma symptom control, asthma-related quality of life and frequent exacerbations.
125-127
Waist circumference and waist-height ratio also predict worse symptoms, supporting a role for fat distribution.
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| Association with other comorbidities
Obesity increases the risk for GERD and OSA, 115 and the effects of these comorbidities on asthma control may be independent of each another. 129 Obesity is also associated with depression. 
| Mechanisms
The pathophysiology underlying DB in patients with asthma is not fully understood. In patients with asthma, voluntary hyperventilation that is sufficient to cause hypocapnia also increases airway resistance, a phenomenon not observed in normal controls. 131 However, even when asthma patients have a similar minute ventilation to normal controls, hypocapnia can be present. 132 This implies that hypocapnia-and associated dysfunctional breathing-may be intrinsic to the pathophysiology of asthma, the underlying mechanism of which remains unclear. 132 Patients with symptomatic asthma have increased tidal volumes and minute ventilation, and greater asynchrony between movements of the rib cage and abdomen. 133 It is uncertain, whether the abnormal breathing pattern leads to more intense symptoms, or whether the abnormal breathing pattern is driven by more severe asthma. 46 In asthma, the presence of DB is associated with increased ED visits, GP visits, limitation of activity and reduced physical and mental health. 136, 137 In patients with difficult asthma, DB is independently associated with poorer asthma control and asthma-related quality of life, even when adjusted for other comorbidities and conventional lung function and inflammatory parameters. 
| Association with other comorbidities
Dysfunctional breathing has been commonly described in patients with anxiety disorders such as panic disorders. 138, 139 One study also demonstrated an independent association between DB and VCD. 
| Influence on asthma outcomes
The presence of depression and anxiety affects a patient's self-management of asthma and is associated with worse asthma symptom control, poorer quality of life and a higher likelihood of asthmarelated hospitalizations, 42, 143, 144 although this is not a universal finding. 145 The presence of anxiety also increases the risk of long-term work disability in asthma. 
| Association with other comorbidities
The associations between anxiety and depression with other comorbidities of obesity, dysfunctional breathing and VCD have been discussed. Interestingly, a study examining the relationship between asthma, obesity and depression found that the effect of obesity on poor asthma control was completely mediated by depression. 
| Summary of comorbidity contribution to difficult asthma
While direct causation is difficult to prove, overwhelming evidence from the literature demonstrates a close association between individual comorbidities and adverse asthma outcomes (Table 1) . Multiple comorbidities commonly coexist in each difficult asthma patient.
We observe that for each comorbidity discussed, associations have been described with two-to-five other comorbidities (Figure 1 ).
Further work is needed to examine the interplay between multiple comorbidities within a single individual with difficult asthma. Not only may comorbidities impact other comorbidities and asthma independently, it is also possible that specific clusters of comorbidities may develop in difficult asthma, which then exert an aggregate effect on the individual's asthma outcomes.
| DOES TR EATMEN T OF COMORBIDITIES IMPROVE DIFFICULT ASTHMA?
| Allergic and nonallergic rhinitis
In patients with rhinitis and mild intermittent asthma, the use of intranasal corticosteroids (INCS) compared to intranasal placebo improves asthma symptoms 148 and health-related quality of life. 149 However, in patients with persistent asthma on inhaled corticosteroids (ICS), the addition of INCS improves nasal symptoms but not asthma control. [150] [151] [152] There is no data on the effect of INCS on asthma control in patients with rhinitis and difficult asthma.
Allergen-specific immunotherapy for allergic rhinitis has durable effects. 153 Immunotherapy has also been shown to improve asthma symptoms and reduce bronchial hyperresponsiveness, regardless of the presence of allergic rhinitis. 154 However, subcutaneous immunotherapy (SCIT) can be associated with systemic adverse reactions and uncontrolled asthma is considered an absolute contraindication for immunotherapy. 155 Immunotherapy via the sublingual route (SLIT) has fewer systemic adverse effects. 156 House dust mite (HDM) SLIT in asthma patients has been shown to prolong the time to asthma destabilization following weaning of ICS treatment. 157 The role of either SCIT or SLIT in patients with rhinitis and difficult has not been extensively explored.
| Chronic rhinosinusitis
Some studies have shown improvements in asthma control following either surgery or medical CRS treatment. 158, 159 Among 17 steroid-dependent patients with difficult asthma, surgery for CRS and nasal polyposis reduced airflow obstruction, and nine patients could be weaned off oral corticosteroids completely. 160 Another group of difficult asthma patients had improved quality of life and reduced asthma-related clinic visits following CRS surgery. 
| Gastroesophageal reflux
A systematic review in 2003 found no consistent effect of medical treatment of GERD on asthma outcomes. 162 Most of the randomized controlled trials of proton-pump inhibition since the review was published also found either no, or clinically insignificant, effects on asthma symptoms, quality of life, 163 exacerbations 164 or lung function. 165 Only one study using lansoprazole in patients with GERD symptoms showed a reduction in asthma exacerbation rates. 166 The effect of medical GERD treatment in difficult or severe asthma is unclear.
Studies looking at surgical treatment of GERD are more promising.
In a placebo-controlled trial of 90 patients with wheezing and GERD, anti-reflux surgery reduced the need for asthma medication. 167 Another randomized controlled trial of patients with asthma and GERD found that Nissen fundoplication 168 significantly improved oesophageal erosions, oesophageal pH and asthma symptoms compared to either placebo or medical treatment groups. The effect of surgical GERD treatment in difficult or severe asthma specifically is not known.
| Obstructive sleep apnoea
Results from observational studies on the use of continuous positive airway pressure (CPAP) in patients with uncontrolled asthma with OSA have been promising. The application of nasal CPAP improves nocturnal symptoms, 169, 170 as well as asthma control and quality of life. 171 The effect of CPAP or other OSA treatments in the context of difficult or severe asthma is unknown.
| Vocal cord dysfunction
Treatment modalities for VCD include nonpharmacological and pharmacological therapies. Speech retraining is the mainstay of treatment for VCD 172 and psychotherapy may be beneficial in some patients. 101 Pharmacological treatment, such as gabapentin and pregabalin, is effective for chronic refractory cough 173, 174 but little efficacy data exist for VCD. Inhaled ipratropium reduced exercise-induced VCD in a small case series. 175 In a small uncontrolled study, treatment of GERD in patients with VCD with lansoprazole improved VCD symptoms in only a minority of patients. 176 The effect of the above-mentioned treatment on asthma control is unclear.
In patients with difficult asthma and VCD, botulinum toxin injection into laryngeal muscles reduced VCD and improved asthma control scores in an uncontrolled case series. 
| Obesity
Randomized controlled trials on weight-loss interventions for obese asthmatics showed promising results. A Cochrane systematic review found that weight loss was associated with improvement in asthma control. 178 A randomized controlled trial conducted in Brazil showed that a short-term weight-loss programme incorporating exercise improved asthma control, asthma-related quality of life and lung function. 179 Observational studies demonstrated that bariatric surgery in obese asthmatics improved asthma symptom control, airway
hyperresponsiveness, asthma quality of life and lung function parameters. [180] [181] [182] [183] Nonsurgical weight-loss methods also showed similar improvements in asthma outcomes. 184 The beneficial effects on asthma were dependent on the magnitude of weight loss. 185, 186 The effect of weight loss may be influenced by the type 2 status of the individual, with improved airway hyperresponsiveness in "type 2 low," but not "type 2 high," patients. 181, 187 On the other hand, improvement in asthma outcomes may occur without changes in airway inflammation, suggesting that mechanisms unrelated to inflammation are also responsible. 
| Anxiety/depression
A randomized trial demonstrated that in asthma patients with anxiety, education combined with cognitive behavioural therapy significantly improved asthma-specific fear, compared to usual clinical management, 192 but asthma-specific outcomes were not examined.
The impact of treatment for anxiety and depression in difficult or severe asthma is unclear.
| Summary for comorbidity treatment effects on difficult asthma outcomes
The current literature suggests that treatment of most extra-pulmonary comorbidities improves asthma outcomes, but this is based mainly on observational studies (Table 1) .
For obesity, gastroesophageal reflux and allergic rhinitis, random- 
| HOW SHOULD CLINICIAN S EVALUATE AND TREAT THESE COMORBIDITIES?
Given the significant impact of extra-pulmonary comorbidities on asthma outcomes, it is critical to identify and manage these comorbidities in patients with difficult asthma. 19 Broadly speaking, there are three approaches to comorbidity assessment.
| Unstructured assessment
Individual respiratory specialists typically assess each comorbidity during the clinical consultation based on history and physical examination. This approach is time-consuming, especially when patients have multiple comorbidities. 45 Furthermore, clinicians are liable to miss important comorbidities. 46 Dysfunctional breathing and vocal cord dysfunction are particularly prone to be overlooked.
| Exhaustive assessment
In contrast to an unstructured approach, some difficult asthma centres put all patients through an extensive battery of investigations and specialist review, including ear, nose and throat (ENT) surgeons, psychiatrists and allied health professionals. 134, 193 This exhaustive approach is unlikely to overlook important comorbidities but is highly resource intensive, often necessitating multi-day admissions. Such methods are not be feasible in most healthcare settings and systems.
F I G U R E 2 A stratified approach to comorbidity assessment. CT, computed tomography; ENT, ear, nose and throat specialist. *See Table 2 and reference (46) for examples of questionnaires that can be used
| Targeted assessment
Our centre has developed a stratified approach to overcome the inherent insensitivity of unstructured comorbidity assessments, as well as to optimize the use of healthcare resources. This approach involves three stages (Figure 2 ): 
| CONCLUSION
Extra-pulmonary comorbidities are important treatable traits to address in all patients with asthma, but particularly in patients with difficult asthma. These comorbidities are highly prevalent in difficult asthma, and multiple comorbidities often coexist in the same patient.
Better definitions and diagnostic methods for some comorbidities, such as vocal cord dysfunction and dysfunctional breathing, are essential for progress in these areas.
Comorbidities substantially influence outcomes in patients with difficult asthma. Available literature demonstrates the adverse impact of these comorbidities on asthma symptom control, asthma quality of life and exacerbation rates.
The presence of a symptomatic comorbidity warrants treatment, regardless of baseline asthma status or asthma control. However, randomized control data supporting the efficacy of comorbidity treatment to improve asthma outcomes are only available for a few comorbidities and, even then, not all the data are positive. This area therefore requires further rigorous research.
Finally, extra-pulmonary comorbidities appear to be under-recognized in the difficult asthma population, even by specialists. On occasion, comorbidity symptoms, in patients without asthma, may even be mistaken for asthma. Therefore, the evaluation of difficult asthma should always incorporate a meticulous search for these comorbidities. We suggest a stratified diagnostic approach which balances comprehensiveness against feasibility and cost.
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